Grilled Cheese

ExploreLog inSign up
Terms of UsePrivacy PolicyCommunity StandardsHelpGet the app

Grilled Cheese is a product of Village Compute

Version devBuilt at: 2026-10-16 08:00:47 EDT

PhotosVideosAllPeople
LatestRanked
Load more
@tctmd.bsky.socialOct 16, 2026, 2:28 PM

Two novel incretin-based agents appear highly effective in type 2 diabetes, with the TRIUMPH-2 and SYNCHRONIZE-2 studies of #retatrutide and #survodutide, respectively, showing reductions in body weight and better glycemic control. https://bit.ly/4yQK8Ef

Photo, no description
@springermedicine.comOct 15, 2026, 10:54 AM

From #EASD2026 - Prof. Elif Ekinci shares the efficacy and safety findings from TRIUMPH-2, a phase 3 trial of the GIP, GLP-1, and glucagon receptor agonist #retatrutide in patients with type 2 diabetes and obesity.

Watch the full interview 👉️ buff.ly/sivRg5m

#DiabetesCare

@omni-letters.bsky.socialOct 12, 2026, 1:46 PM

Estudo mostra que o retatrutide, novo medicamento, é promissor no tratamento da obesidade e diabetes tipo 2, com significativa perda de peso e melhor controle glicêmico em 80 semanas de ensaio clínico.

#retatrutide #obesidade #diabetes #saude #medicamentos

@vogewekwannalawm.bsky.socialOct 12, 2026, 9:24 AM

Tirz vs Reta - what the trials show:

Tirz: dual agonist, proven, less supply issues
Reta: triple agonist, early data shows +24% fat mass loss vs +14% lean

My research notes: link in profile.

#Retatrutide #Tirzepatide #Peptides #GLP1Research #SleepApnea #Biohacking

Photo, no descriptionPhoto, no descriptionPhoto, no descriptionPhoto, no description
@vogewekwannalawm.bsky.socialOct 12, 2026, 9:21 AM

Reta research month 4: -18kg, sleep apnea from severe to mild.

Game changer was tracking sleep, not just weight.

#Reta #Retatrutide #SleepApnea #Peptides

Photo, no descriptionPhoto, no descriptionPhoto, no description
@vogewekwannalawm.bsky.socialOct 12, 2026, 9:19 AM

EU research community: where are you logging your Reta journey?

I'm tracking:
- weight / waist
- sleep quality (Oura)
- fasting glucose

Results so far: -19kg, sleep apnea symptoms way down.

DM for research chat.

#Retatrutide #EUpeptides #PeptideResearch #SleepApnea #GLP1 #WeightLoss

Photo, no descriptionPhoto, no descriptionPhoto, no description
@vogewekwannalawm.bsky.socialOct 12, 2026, 9:18 AM

6 months on Retatrutide research:

Weight: 128kg -> 105kg
Sleep apnea: severe -> mild (AHI 42 -> 11)
Energy: back

Reta was different than Tirz for me - less nausea, better fat loss.

Not medical advice. n=1.

#Retatrutide #Reta #Peptides #Tirzepatide #GLP1 #SleepApnea #WeightLossJourney #Biohacking

Photo, no descriptionPhoto, no descriptionPhoto, no description
@vogewekwannalawm.bsky.socialOct 12, 2026, 9:16 AM

Retatrutide / Tirzepatide research notes from EU:

- Appetite suppression is real
- Sleep quality improved after -10kg
- Bloodwork before/after is key

Not medical advice - sharing my n=1 research log.

Full log + sources -> link in bio

#Retatrutide #Peptides #Tirzepatide #Biohacking #FatLoss

Photo, no descriptionPhoto, no descriptionPhoto, no description
@vogewekwannalawm.bsky.socialOct 12, 2026, 3:38 AM

For fat loss now, Sleep 7-8h, 100-120g protein, lift 2x week, 0.5kg/week loss max2
I don't sell, don't give sources, not medical advice - talk to your GP

#peptides #retatrutide #weightloss #glp1 #biohacking #fatloss #healthresearch #weightlossjourney #blueskyhealth #euhealth #cpap #london #leed

@purepeptides.bsky.socialOct 6, 2026, 10:22 PM

✨ New week, new giveaway! ✨ Win a FREE vial — winner's choice of Reta 15mg, TIRZ 30mg, or Semax 10mg! To enter: create your free account at purespeptides.com. New signups get $10 off first order with TAKE10. Winner picked Friday! 🧪 #peptides #GLP-1 #Retatrutide

@foodnourish.bsky.socialOct 6, 2026, 7:10 AM

📣 New Podcast! "Retatrutide Weight Loss and Gray Market Risks" on @Spreaker #agonist #clinical #diabetes #dosage #glucagon #health #healthcare #incretin #medicine #metabolism #nutrition #obesity #peptide #pharmacovigilance #research #retatrutide #safety #sideeffects #trial #wellness

@midgardfinance.comOct 5, 2026, 7:00 AM

💉 #obesity #EASD2026

🇺🇸 $LLY #retatrutide took off 18.8% in type 2 diabetes, the most of six drugs. 🇩🇪 Boehringer's #survodutide, from 🇩🇰 $ZEAL: 9.8%, and 26% stopped for side effects. All randomised patients.

All of EASD in one post:
midgardfinance.com/blog/2026/10/04/easd-2026-roundup/

Horizontal bar chart titled "Weight loss with type 2 diabetes": weight lost by adults with obesity and type 2 diabetes on the top dose of six drugs, each beside its own trial's placebo, counting all randomised patients. Retatrutide 12 mg (TRIUMPH-2, 80 weeks): 18.8% against 5.1% on placebo. Tirzepatide 15 mg (SURMOUNT-2, 72 weeks): 14.7% against 3.2% on placebo. CagriSema 2.4/2.4 mg (REDEFINE 2, 68 weeks): 13.7% against 3.4% on placebo. Semaglutide 7.2 mg (STEP UP T2D, 72 weeks): 13.2% against 3.9% on placebo. Survodutide 6.0 mg (SYNCHRONIZE-2, 76 weeks): 9.8% against 3.9% on placebo. Orforglipron 36 mg (ATTAIN-2, 72 weeks): 9.6% against 2.5% on placebo. Retatrutide and survodutide, the two trials read out at the EASD congress, are drawn in purple and the other four in grey. These are separate trials of 68 to 80 weeks, not a head-to-head comparison.
@midgardfinance.comOct 2, 2026, 7:00 AM

💉 #obesity

🇺🇸 #Retatrutide in TRIUMPH-1: 27% of patients lost more than a THIRD of their body weight at 80 weeks. The Phase 2 trial never reported that threshold.

At 30%+: 45% vs 26%. Longer trial, deeper loss.

midgardfinance.com/obesity/drugs/retatrutide/

$LLY

Grouped bar chart comparing retatrutide 12 mg against itself at two stages of its programme, showing the share of patients reaching each weight-loss threshold. Grey bars are the phase 2 trial at 48 weeks, which has no acronym, and blue bars the phase 3 trial TRIUMPH-1 at 80 weeks. At 25 per cent or more of body weight lost, Phase 2 reached 48 per cent of patients and Phase 3 62. At 30 per cent or more, Phase 2 reached 26 and Phase 3 45. At 35 per cent or more, Phase 3 reached 27 per cent and Phase 2 is absent because that trial never reported the threshold, which is labelled on the chart rather than drawn as a zero. Both readings are the efficacy estimand, the adherent population, so they are matched on that axis. They are not matched on duration: the Phase 3 trial ran 32 weeks longer, so part of every gap is more time on treatment rather than a difference between the programmes. The Phase 2 figures come from the published trial paper; the Phase 3 figures come from a sponsor press release, which is the primary source until the trial publishes but is a tier below a peer-reviewed table.
@quartzmedia.bsky.socialOct 1, 2026, 12:22 PM

ICYMI: Eli Lilly's new drug just shattered weight loss records in diabetes trials #EliLilly #Retatrutide

@pharmaj.bsky.socialOct 1, 2026, 11:15 AM

Clinical trial participants with #obesity and type 2 diabetes mellitus, who took #retatrutide at a dose of 12 mg, experienced an average of 20.8% weight loss over 80 weeks, study results show

#ukpharmacy #diabetes

buff.ly/mpbfIZE

@byalung.bsky.socialOct 1, 2026, 8:59 AM

Retatrutide produced an average 18.8% weight loss over 80 weeks in adults with obesity and type 2 diabetes in the TRIUMPH-2 phase 3 trial. #Retatrutide #WeightLoss #Diabetes

➡️: www.medicaldaily.co.uk/experimental...

Photo, no description
@thelancetendo.bsky.socialOct 1, 2026, 7:44 AM

Published in @thelancet.com

#Retatrutide in adults with #obesity and type 2 #diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial www.thelancet.com/journals/lan...
#T2D
#EASD2026

#MedSky #EndoSky

@midgardfinance.comSep 30, 2026, 12:30 PM

💉 #obesity #EASD2026

🇺🇸 Lilly's #retatrutide 12 mg, 80 weeks, two Phase 3 trials published this week:

Without diabetes (TRIUMPH-1, NEJM): -28.3%
With type 2 diabetes (TRIUMPH-2, Lancet): -20.8%

Same drug, same dose. Type 2 diabetes costs about a quarter of the weight loss.

$LLY

Line chart of average weight change over 80 weeks on retatrutide 12 mg in two phase 3 trials published on 29 September 2026. The line that falls further is TRIUMPH-1 (New England Journal of Medicine), adults with obesity and no diabetes; the shallower line is TRIUMPH-2 (The Lancet), adults with obesity and type 2 diabetes. Both lines fall steeply for the first 36 weeks and flatten after week 52. The lines show the published average of patients on treatment, ending at -27.6 and -21.3 per cent at week 80. The two dots to the right are each trial's estimate for patients who stayed on the drug: -28.3 per cent without diabetes and -20.8 per cent with type 2 diabetes, a gap of 7.5 points. These are separate trials with different participants, so the gap is not a randomised comparison, although the drug, dose, duration and method are the same.
@pharmaphorum.bsky.socialSep 30, 2026, 11:24 AM

#EliLilly's triple G agonist #retatrutide has achieved impressive #weightloss in patients with #type2diabetes and #obesity, boosting its credentials as the next big thing in #cardiometabolicdiseases.

pharmaphorum.com/news/lilly-f...

Photo, no description
@rckjnsn.eurosky.socialSep 29, 2026, 10:30 PM

O, kijk, weer een nieuwe! #Retatrutide

“‘Godzilla’ of weight-loss drugs could provide other important health benefits”

www.theguardian.com/science/2026...